Physician profile
Henry E Reyes
NPI 1144456880
$8,278.45
in general payments reported to CMS, 2019-2025
42 companies · $3,752 in 2025
The $3,752 reported for 2025 was more than what 84% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $628 · 2021: $221 · 2022: $1,097 · 2023: $764 · 2024: $1,679 · 2025: $3,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $2,445 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $2,445.28 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $4,302.09 | 2022-2025 | Gelpoint V-Path |
| Astrazeneca Pharmaceuticals LP | $1,009.18 | 2019-2025 | Lynparza, Calquence, Enhertu |
| Glaxosmithkline, LLC. | $567.62 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Eisai INC. | $378.61 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $227.53 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $205.17 | 2020-2025 | Talvey, Rybrevant, Darzalex |
| Abbvie INC. | $181.65 | 2024-2025 | |
| Biom'Up France Sas | $152.25 | 2020 | |
| Stryker Corporation | $149.99 | 2023 | 1688 |
| Mayne Pharma Commercial LLC | $124.99 | 2023 | |
| Genzyme Corporation | $97.60 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.91 | 2022-2025 | Ninlaro, Fruzaqla |
| Novartis Pharmaceuticals Corporation | $90.88 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $43.63 | 2024-2025 | Libtayo |
| Seagen INC. | $43.37 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.